Psychemedics (PMDI) 10-Q 10 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 04, 2022
Document Information [Line Items]
Entity Central Index Key	0000806517
Entity Registrant Name	PSYCHEMEDICS CORP
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	1-13738
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-1701987
Entity Address, Address Line One	289 Great Road
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
City Area Code	978
Local Phone Number	206-8220
Title of 12(b) Security	Common stock. $0.005 par value
Trading Symbol	PMD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,644,696

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 3,458	$ 1,992
Accounts receivable, net of allowance for doubtful accounts of $118 at September 30, 2022, and $89 at December 31, 2021	4,953	4,116
Prepaid expenses and other current assets	1,510	1,499
Income tax receivable	803	2,678
Total Current Assets	10,724	10,285
Fixed assets, net of accumulated amortization and depreciation of $21,449 at September 30, 2022, and $19,659 at December 31, 2021	5,064	6,691
Other assets	843	864
Net deferred tax assets	935	160
Operating lease right-of-use assets	2,912	3,552
Total Assets	20,478	21,552
Current Liabilities:
Accounts payable	857	994
Accrued expenses	3,974	3,188
Current portion of long-term debt	360	664
Current portion of operating lease liabilities	985	984
Total Current Liabilities	6,176	5,830
Long-term debt	380	599
Long-term portion of operating lease liabilities	2,200	2,880
Total Liabilities	8,756	9,309
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.005 par value; 50,000 shares authorized, 6,313 shares and 6,257 shares issued at September 30, 2022, and December 31, 2021, respectively, and 5,645 shares outstanding and 5,589 shares outstanding at September 30, 2022, and December 31, 2021, respectively	32	31
Additional paid-in capital	34,139	33,478
Accumulated deficit	(10,733)	(9,550)
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated other comprehensive loss	(1,634)	(1,634)
Total Shareholders' Equity	11,722	12,243
Total Liabilities and Shareholders' Equity	$ 20,478	$ 21,552

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands	Sep. 30, 2022	Dec. 31, 2021
Allowance for doubtful accounts	$ 118,000	$ 89,000
Accumulated depreciation and amortization	$ 21,449	$ 19,659
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized (in shares)	873	873
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares issued (in shares)	6,313	6,257
Common stock, shares outstanding (in shares)	5,645	5,589
Treasury stock, shares (in shares)	668	668

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues	$ 6,516	$ 6,673	$ 19,537	$ 18,473
Cost of revenues	4,184	3,598	12,492	10,394
Gross profit	2,332	3,075	7,045	8,079
Operating expenses:
General & administrative	1,588	1,329	4,360	4,138
Marketing & selling	791	652	2,409	1,950
Research & development	328	244	1,003	817
Total operating expenses	2,707	2,225	7,772	6,905
Operating (loss) income	(375)	850	(727)	1,174
Other (expense) income:
Forgiveness of PPP loan	0	(2,181)	0	(2,181)
Settlement	0	(2,075)	0	(2,075)
Other	(8)	(31)	49	(44)
Total other (expense) income	(8)	75	49	62
(Loss) income before (benefit from) provision for income taxes	(383)	925	(678)	1,236
(Benefit from) provision for income taxes	(286)	186	(282)	280
Net (loss) income	$ (97)	$ 739	$ (396)	$ 956
Basic net (loss) income per share (in dollars per share)	$ (0.02)	$ 0.13	$ (0.07)	$ 0.17
Diluted net (loss) income per share (in dollars per share)	(0.02)	0.13	(0.07)	0.17
Dividends declared per share (in dollars per share)	$ 0.07	$ 0	$ 0.14	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2020	6,205		668
Balance at Dec. 31, 2020	$ 31,000	$ 32,803,000	$ (10,082,000)	$ (8,606,000)	$ (1,634,000)	$ 12,512,000
Shares issued – vested (in shares)	5		0
Stock compensation expense	$ 0	564,000	$ 0	0	0	564,000
Net (loss) income	$ 0		$ 0	956,000	0	956,000
Shares issued – vested (in shares)	5		0
Tax withholding related to vested shares from employee stock plans	$ 0	(5,000)	$ 0	0	0
Balance (in shares) at Sep. 30, 2021	6,210		668
Balance at Sep. 30, 2021	$ 31,000	33,362,000	$ (10,082,000)	(7,650,000)	(1,634,000)	14,027,000
Balance (in shares) at Jun. 30, 2021	6,209		668
Balance at Jun. 30, 2021	$ 31,000	33,189,000	$ (10,082,000)	(8,389,000)	(1,634,000)	13,115,000
Shares issued – vested (in shares)	1		0
Stock compensation expense	$ 0	178,000	$ 0	0	0	178,000
Net (loss) income	$ 0	0	$ 0	739,000	0	739,000
Shares issued – vested (in shares)	1		0
Tax withholding related to vested shares from employee stock plans	$ 0	(5,000)	$ 0	0	0	(5,000)
Balance (in shares) at Sep. 30, 2021	6,210		668
Balance at Sep. 30, 2021	$ 31,000	33,362,000	$ (10,082,000)	(7,650,000)	(1,634,000)	14,027,000
Balance (in shares) at Dec. 31, 2021	6,257		668
Balance at Dec. 31, 2021	$ 31,000	33,478,000	$ (10,082,000)	(9,550,000)	(1,634,000)	12,243,000
Shares issued – vested (in shares)	55		0
Shares issued – vested	$ 1,000	(1,000)	$ 0	0	0	0
Stock compensation expense	0	694,000	0	0	0	694,000
Cash dividends declared	0	0	0	(787,000)	0	(787,000)
Net (loss) income	$ 0	0	$ 0	(396,000)	0	$ (396,000)
Exercise of stock options (in shares)	1		0			1
Exercise of stock options	$ 0	4,000	$ 0	0	0	$ 4,000
Shares issued – vested (in shares)	55		0
Tax withholding related to vested shares from employee stock plans	$ 0	(36,000)	$ 0	0	0	(36,000)
Balance (in shares) at Sep. 30, 2022	6,313		668
Balance at Sep. 30, 2022	$ 32,000	34,139,000	$ (10,082,000)	(10,733,000)	(1,634,000)	11,722,000
Balance (in shares) at Jun. 30, 2022	6,294		668
Balance at Jun. 30, 2022	$ 31,000	33,863,000	$ (10,082,000)	(10,242,000)	(1,634,000)	11,936,000
Shares issued – vested (in shares)	19		0
Shares issued – vested	$ 1,000	(1,000)	$ 0	0	0	0
Stock compensation expense		277	0	0	0	277
Cash dividends declared	0	0	0	(394,000)	0	(394,000)
Net (loss) income	$ 0	0	$ 0	(97,000)	0	(97,000)
Shares issued – vested (in shares)	19		0
Balance (in shares) at Sep. 30, 2022	6,313		668
Balance at Sep. 30, 2022	$ 32,000	$ 34,139,000	$ (10,082,000)	$ (10,733,000)	$ (1,634,000)	$ 11,722,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Dividends declared, per share (in dollars per share)	$ 0.07	$ 0.07

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (396)	$ 956
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Forgiveness of PPP loan	0	(2,181)
Depreciation and amortization	1,836	2,134
ROU asset amortization	718	697
Deferred income taxes	(775)	79
Stock-based compensation	694	564
Changes in operating assets and liabilities:
Accounts receivable	(837)	(1,325)
Prepaid expenses and other current assets	(11)	(1,840)
Income tax receivable	1,875	226
Accounts payable	(137)	(129)
Operating lease liabilities	(757)	(754)
Accrued expenses	786	1,422
Net cash provided by (used in) operating activities	2,996	(151)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment and leasehold improvements	(60)	(68)
Cost of internally developed software	(103)	(84)
Other assets	(25)	(42)
Net cash used in investing activities	(188)	(194)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of stock	4	0
Employee payroll tax withholding on stock issued under the stock-based compensation plans	(36)	(5)
Payments of equipment financing	(523)	(515)
Cash dividends paid	(787)	0
Net cash used in financing activities	(1,342)	(520)
Net increase (decrease) in cash	1,466	(865)
Cash, beginning of period	1,992	2,833
Cash, end of period	3,458	1,968
Supplemental Disclosures of Cash Flow Information:
Cash paid for income taxes	0	10
Cash paid for interest	36	40
Cash paid for operating leases	849	862
Right-of-use assets acquired through operating leases	$ 78	$ 193

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Basis of Presentation The interim condensed consolidated financial statements of Psychemedics Corporation (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10 not December 31, 2021, 2021 10 “10 The condensed consolidated balance sheet as of September 30, 2022, three nine September 30, 2022, 2021, three nine September 30, 2022, 2021, nine September 30, 2022, 2021 December 31, 2021, not The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three nine September 30, 2022, may not may December 31, 2022, Unless the context requires otherwise, the terms “we”, “us”, “our”, or “the Company” refer to Psychemedics Corporation and its wholly-owned consolidated subsidiaries.

Note 2 - COVID-19 Pandemic

Note 2 - COVID-19 Pandemic	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Effect of Covid-19 Pandemic [Text Block]	2. Effects of COVID- 19 The outbreak of coronavirus (“COVID- 19” 19 19’s The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on March 27, 2020, December 2020, 19. 19 September 30, 2021. three nine September 30, 2021, 2020 third 2022, Liquidity and Management s Plans At September 30, 2022, 12 may not no Accounts Receivable The Company believes its allowance for credit losses related to its accounts receivable remained adequate as of September 30, 2022, not

Note 3 - Stock-based Compensati

Note 3 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	3. Stock-Based Compensation The Company’s 2006 September 30, 2022, Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). The compensation cost charged against income is included in cost of revenues and operating expenses as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Stock-based compensation related to: Stock option grants $ 20 $ 53 $ 114 $ 275 Stock unit awards 257 125 580 289 Total stock-based compensation $ 277 $ 178 $ 694 $ 564 There was no three nine September 30, 2022, 2021. A summary of the Company’s stock option activity for the nine September 30, 2022, Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Contractual Life Intrinsic Shares Per Share (years) Value (1) Outstanding, December 31, 2021 574 $ 14.23 6.1 $ 100 Granted - $ - Exercised (1 ) $ 4.07 Forfeited (1 ) $ 4.07 Outstanding, September 30, 2022 572 $ 14.28 5.3 $ 74 Exercisable, September 30, 2022 519 $ 14.89 5.1 $ 21 ( 1 Intrinsic value is calculated based on the amount by which the closing market value of the Company’s stock exceeded the exercise price of the underlying options, multiplied by the number of shares. A summary of the Company’s stock unit award (“SUA”) activity for the nine September 30, 2022, Number of Shares Weighted Average Grant-Date Fair Value Per Share Outstanding & Unvested, December 31, 2022 224 $ 5.48 Granted 146 $ 6.53 Converted to common stock (55 ) $ 6.43 Cancelled (6 ) $ 6.43 Forfeited (31 ) $ 6.19 Outstanding & Unvested, September 30, 2022 278 $ 5.79 As of September 30, 2022, September 30, 2022, The Board of Directors approved the accelerated vesting of 19 thousand and 35 thousand SUAs to certain directors, upon retirement, of the Company during the three nine September 30, 2022, three nine September 30, 2022,

Note 4 - Basic and Diluted Net

Note 4 - Basic and Diluted Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common and dilutive common equivalent shares outstanding during the period when the effect is dilutive. The number of dilutive common equivalent shares outstanding during the period was determined in accordance with the treasury-stock method. Common equivalent shares consisted of common stock issuable upon the exercise of outstanding options and common stock issuable upon the vesting of outstanding, unvested SUAs. Basic and diluted weighted average common shares outstanding for the three nine September 30, 2022, 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Weighted average common shares outstanding, basic 5,638 5,542 5,613 5,542 Dilutive common equivalent shares - 84 - 72 Weighted average common shares outstanding, diluted 5,638 5,626 5,613 5,614 The computation of diluted earnings (loss) per share for the three nine September 30, 2022, 2021 three nine September 30, 2022,

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	5. Commitments and Contingencies From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. The Company continuously assesses the potential liability related to the Company’s pending litigation and revises its estimates when additional information becomes available. Although it is difficult to predict the ultimate outcome of these cases, management believes, that any ultimate liability would not Settlements As previously reported in the 10 December 6, 2021, No. 2:20 06624 In the binding MOU, the parties agreed to settle this matter for a payment by the Company of $1.2 million in exchange for the dismissal of the California Lawsuit and a customary release of liability, subject only to final court approval and the process described below. Factoring in that process, the Company estimates that the settlement funds will be dispersed in the second 2023, Although the Company believes that the allegations in the California Lawsuit lack merit, it agreed at a mediation to enter into the binding MOU to settle the claims in the California Lawsuit in order to avoid potentially significant legal fees, other expenses, and management time that would have to be devoted to protracted litigation in California regarding its wage and hour laws. The foregoing was also impacted in part by new California case law in February 2021 June 9, 2017 The MOU assumes class certification for purposes of the settlement only. The settlement amount of $1.2 not 2004. September 30, 2022,

Note 6 - Operating Leases

Note 6 - Operating Leases	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. Operating Leases The Company has five one not As of September 30, 2022, September 30, 2022, September 30, 2022, three nine September 30, 2022, Maturities and balance sheet presentation of the Company’s lease liabilities for all operating leases as of September 30, 2022, October 1, 2022, through December 31, 2022 $ 238 2023 1,133 2024 1,061 2025 553 2026 460 Total Lease Payments 3,445 Less: Interest expense (260 ) Present value of lease liabilities $ 3,185 Current operating lease liabilities $ 985 Long-term operating lease liabilities 2,200 $ 3,185

Note 7 - Debt and Other Financi

Note 7 - Debt and Other Financing Arrangements	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Debt and Other Financing Arrangements On March 20, 2014, August 8, 2014, September 15, 2015, October 30, 2017, December 2, 2019. 10 The weighted average interest rate on outstanding debt under the Loan Agreement for the three nine September 30, 2022, three nine September 30, 2022. September 30, 2022, September 30, 2022. The annual principal repayment requirements for debt obligations as of September 30, 2022, October 1, 2022, through December 31, 2022 $ 141 2023 294 2024 305 Long-term debt from equipment financing 740 Less: current portion of long-term debt from equipment financing (360 ) Long-term debt from equipment financing, net of current portion $ 380

Note 8 - Revenue

Note 8 - Revenue	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	8. Revenue The table below disaggregates our external revenue by major source (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Testing $ 5,554 $ 5,859 $ 16,759 $ 16,275 Shipping/Collection (hair) 937 774 2,687 2,069 Other 25 40 91 129 Total Revenue $ 6,516 $ 6,673 $ 19,537 $ 18,473

Note 9 - Significant Customers

Note 9 - Significant Customers	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	9. Significant Customers The Company had no customers that represented over 10% nine September 30, 2022, 2021. September 30, 2022. 10% December 31, 2021.

Note 10 - Subsequent Events

Note 10 - Subsequent Events	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	10. Subsequent Events On November 9, 2022, December 16, 2022, December 2, 2022.

Note 3 - Stock-based Compensa_2

Note 3 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Cost by Plan [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Stock-based compensation related to: Stock option grants $ 20 $ 53 $ 114 $ 275 Stock unit awards 257 125 580 289 Total stock-based compensation $ 277 $ 178 $ 694 $ 564
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Price Contractual Life Intrinsic Shares Per Share (years) Value (1) Outstanding, December 31, 2021 574 $ 14.23 6.1 $ 100 Granted - $ - Exercised (1 ) $ 4.07 Forfeited (1 ) $ 4.07 Outstanding, September 30, 2022 572 $ 14.28 5.3 $ 74 Exercisable, September 30, 2022 519 $ 14.89 5.1 $ 21
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Shares Weighted Average Grant-Date Fair Value Per Share Outstanding & Unvested, December 31, 2022 224 $ 5.48 Granted 146 $ 6.53 Converted to common stock (55 ) $ 6.43 Cancelled (6 ) $ 6.43 Forfeited (31 ) $ 6.19 Outstanding & Unvested, September 30, 2022 278 $ 5.79

Note 4 - Basic and Diluted Ne_2

Note 4 - Basic and Diluted Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Weighted average common shares outstanding, basic 5,638 5,542 5,613 5,542 Dilutive common equivalent shares - 84 - 72 Weighted average common shares outstanding, diluted 5,638 5,626 5,613 5,614

Note 6 - Operating Leases (Tabl

Note 6 - Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	October 1, 2022, through December 31, 2022 $ 238 2023 1,133 2024 1,061 2025 553 2026 460 Total Lease Payments 3,445 Less: Interest expense (260 ) Present value of lease liabilities $ 3,185 Current operating lease liabilities $ 985 Long-term operating lease liabilities 2,200 $ 3,185

Note 7 - Debt and Other Finan_2

Note 7 - Debt and Other Financing Arrangements (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	October 1, 2022, through December 31, 2022 $ 141 2023 294 2024 305 Long-term debt from equipment financing 740 Less: current portion of long-term debt from equipment financing (360 ) Long-term debt from equipment financing, net of current portion $ 380

Note 8 - Revenue (Tables)

Note 8 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Testing $ 5,554 $ 5,859 $ 16,759 $ 16,275 Shipping/Collection (hair) 937 774 2,687 2,069 Other 25 40 91 129 Total Revenue $ 6,516 $ 6,673 $ 19,537 $ 18,473

Note 2 - COVID-19 Pandemic (Det

Note 2 - COVID-19 Pandemic (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2021
Income Tax Benefit CARES Act		$ 1,000	$ 2,600
Proceeds from Income Tax Refunds	$ 1,900
Cash and Cash Equivalents, at Carrying Value, Total	$ 3,458			$ 1,992

Note 3 - Stock-based Compensa_3

Note 3 - Stock-based Compensation (Details Textual) - Incentive Plan 2006 [Member] shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	176	176
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	1,136	1,136
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 1,200	$ 1,200
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 10 months 24 days
Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number (in shares)	19	35
Share-Based Payment Arrangement, Accelerated Cost | $	$ 118	$ 230

Note 3 - Stock-based Compensa_4

Note 3 - Stock-based Compensation - Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based compensation	$ 277	$ 178	$ 694	$ 564
Share-Based Payment Arrangement, Option [Member]
Share-based compensation	20	53	114	275
Stock Unit Awards [Member]
Share-based compensation	$ 257	$ 125	$ 580	$ 289

Note 3 - Stock-based Compensa_5

Note 3 - Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2022	Dec. 31, 2021
Outstanding (in shares)		574
Outstanding, weighted average exercise price (in dollars per share)		$ 14.23
Outstanding, weighted average remaining contractual life (Year)		5 years 3 months 18 days	6 years 1 month 6 days
Outstanding, aggregate intrinsic value	[1]	$ 74	$ 100
Granted (in shares)		0
Granted, weighted average exercise price (in dollars per share)		$ 0
Exercised (in shares)		(1)
Exercised, weighted average exercise price (in dollars per share)		$ 4.07
Forfeited (in shares)		(1)
Forfeited, weighted average exercise price (in dollars per share)		$ 4.07
Outstanding (in shares)		572	574
Outstanding, weighted average exercise price (in dollars per share)		$ 14.28	$ 14.23
Exercisable (in shares)		519
Exercisable, weighted average exercise price (in dollars per share)		$ 14.89
Exercisable, weighted average remaining contractual life (Year)		5 years 1 month 6 days
Exercisable, aggregate intrinsic value	[1]	$ 21
[1]Intrinsic value is calculated based on the amount by which the closing market value of the Company’s stock exceeded the exercise price of the underlying options, multiplied by the number of shares.

Note 3 - Stock-based Compensa_6

Note 3 - Stock-based Compensation - Nonvested Award Activity (Details) - Stock Unit Award [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Outstanding & Unvested at beginning of period (in shares) | shares	224
Outstanding & Unvested, beginning of period, weighted average price per share (in dollars per share) | $ / shares	$ 5.48
Granted (in shares) | shares	146
Granted, weighted average price per share (in dollars per share) | $ / shares	$ 6.53
Converted to common stock (in shares) | shares	(55)
Converted to common stock, weighted average price per share (in dollars per share) | $ / shares	$ 6.43
Cancelled (in shares) | shares	(6)
Cancelled, weighted average price per share (in dollars per share) | $ / shares	$ 6.43
Forfeited (in shares) | shares	(31)
Forfeited, weighted average price per share (in dollars per share) | $ / shares	$ 6.19
Outstanding & Unvested at end of period (in shares) | shares	278
Outstanding & Unvested, end of period, weighted average price per share (in dollars per share) | $ / shares	$ 5.79

Note 4 - Basic and Diluted Ne_3

Note 4 - Basic and Diluted Net Income (Loss) Per Share (Details Textual) - shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	773	605

Note 4 - Basic and Diluted Ne_4

Note 4 - Basic and Diluted Net Income (Loss) Per Share - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Weighted average common shares outstanding, basic (in shares)	5,638	5,542	5,613	5,542
Dilutive common equivalent shares (in shares)	0	84	0	72
Weighted average common shares outstanding, diluted (in shares)	5,638	5,626	5,613	5,614

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Details Textual) - Enma Sagastume v. Psychemedics Corporation [Member] - USD ($) $ in Millions	Dec. 06, 2021	Sep. 30, 2022
Litigation Settlement, Amount Awarded to Other Party	$ 1.2
Loss Contingency Accrual, Ending Balance		$ 1.2

Note 6 - Operating Leases (Deta

Note 6 - Operating Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Operating Lease, Right-of-Use Asset	$ 2,912	$ 2,912	$ 3,552
Operating Lease, Liability, Total	$ 3,185	$ 3,185
Operating Lease, Weighted Average Discount Rate, Percent	3.80%	3.80%
Operating Lease, Weighted Average Remaining Lease Term (Year)	3 years 4 months 24 days	3 years 4 months 24 days
Operating Lease, Expense	$ 262	$ 762

Note 6 - Operating Leases - Mat

Note 6 - Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
October 1, 2022, through December 31, 2022	$ 238
2023	1,133
2024	1,061
2025	553
2026	460
Total Lease Payments	3,445
Less: Interest expense	(260)
Present value of lease liabilities	3,185
Current operating lease liabilities	985	$ 984
Long-term operating lease liabilities	$ 2,200	$ 2,880

Note 7 - Debt and Other Finan_3

Note 7 - Debt and Other Financing Arrangements (Details Textual) - Line of Credit [Member] - Equipment Loan Arrangement [Member] - Banc of America Leasing and Capital [Member] $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Long-Term Debt, Weighted Average Interest Rate, over Time	3.70%	3.60%
Interest Expense, Total	$ 8	$ 26
Long-Term Debt, Weighted Average Interest Rate, at Point in Time	3.80%	3.80%
Long-Term Debt, Total	$ 740	$ 740

Note 7 - Debt and Other Finan_4

Note 7 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Less: current portion of long-term debt from equipment financing	$ (360)	$ (664)
Long-term debt from equipment financing, net of current portion	380	$ 599
Equipment Loan Arrangement [Member]
October 1, 2022, through December 31, 2022	141
2023	294
2024	305
Long-term debt from equipment financing	740
Less: current portion of long-term debt from equipment financing	(360)
Long-term debt from equipment financing, net of current portion	$ 380

Note 8 - Revenue - Revenue by M

Note 8 - Revenue - Revenue by Major Source (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues	$ 6,516	$ 6,673	$ 19,537	$ 18,473
Testing [Member]
Revenues	5,554	5,859	16,759	16,275
Shipping/Collection (Hair) [Member]
Revenues	937	774	2,687	2,069
Other Revenue [Member]
Revenues	$ 25	$ 40	$ 91	$ 129

Note 9 - Significant Customers

Note 9 - Significant Customers (Details Textual) - Customer Concentration Risk [Member]	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Revenue Benchmark [Member]
Number of Major Customers	0	0
Accounts Receivable [Member]
Number of Major Customers	1
Accounts Receivable [Member] | Customer One [Member]
Number of Major Customers	1
Concentration Risk, Percentage	14%

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - $ / shares		3 Months Ended	9 Months Ended
	Dec. 06, 2022	Sep. 30, 2022	Sep. 30, 2022
Common Stock, Dividends, Per Share, Declared (in dollars per share)		$ 0.07	$ 0.07
Subsequent Event [Member]
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.07